Pacing and clinical electrophysiology : PACE最新文献

{"title":"Optimization of pacemaker pocket-Revisiting the fundamentals.","authors":"Lan Su, Weijian Huang","doi":"10.1111/pace.14360","DOIUrl":"https://doi.org/10.1111/pace.14360","url":null,"abstract":"The incidence of pacemaker-related infections including pocket infection or erosion in previous study was 0.68%, and increased yearly in long-term follow-up.1 Until now, it constantly revisited the old saying how to avoid pocket-related complications and design a nice pocket. In an article published in this issue, Enomoto et al.2 described a single-center retrospective study which included 76 patients with ICD implanted through axillary vein, 31 of whom had pocket located in the axillary region. During an average follow-up time of 4.9 ± 2.3 years, it was found that, as comparedwith those of the45patientswith conventional left anterior chest pocket, the lead parameters were similar, and there were no complications such as lead failure or pocket infections. Different from the previous case reports, this study had the longest follow-up time and the largest sample size to date, verified the feasibility and safety of the axillary pocket for large volume devices. The main novel points and research value of this study are as follows:","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1807-1809"},"PeriodicalIF":1.8,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/pace.14360","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39434682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Independent factors of low radiation dose during atrial fibrillation ablation with cryoballoon or radiofrequency: Results from the \"Go for zero fluoroscopy\" registry.","authors":"Matthieu Gras,&nbsp;Rodrigue Garcia,&nbsp;Victor Waldmann,&nbsp;Vincent Bergère,&nbsp;David Duncker,&nbsp;Tom De Potter,&nbsp;Lukas Fiedler,&nbsp;Francisco Moscoso Costa,&nbsp;Bor Antolič,&nbsp;Jedrzej Kosiuk","doi":"10.1111/pace.14366","DOIUrl":"https://doi.org/10.1111/pace.14366","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) catheter ablation is a common procedure requiring in most cases the use of fluoroscopy. We aimed to evaluate the factors associated with a lower dose of fluoroscopy used during AF ablation with cryoballoon or radiofrequency.</p><p><strong>Methods: </strong>In this prospective European registry, centers were requested to provide procedural characteristics of consecutive AF ablation cases. Lower doses of fluoroscopy were defined as those with dose-area-product (DAP) under the median dose used in the radiofrequency and the cryoballoon ablation groups.</p><p><strong>Results: </strong>A total of 638 AF ablation procedures were collected (n = 492 for radiofrequency and n = 146 for cryoballoon ablation groups) in 25 centers. The median [IQR] DAP were 926 [349;2092] and 1516 [418;3408] cGy*cm² in the radiofrequency and cryoballoon groups, respectively. Main factors associated with lower DAP in cryoballoon ablation group were electrophysiology dedicated laboratory (OR 6.04, 95%CI 1.16-31.54; P = .03) and frequent dosimetry report (OR 21.39, 95%CI 5.43-98.54; P = .03). Main factors associated with lower DAP in the radiofrequency ablation group were the use of a chest dosimeter (OR 12.57, 95% CI 2.88-54.90; P = .01), biplane X-ray equipment (OR 3.12, 95%CI 1.89-5.16; P < .01), university hospital (OR 2.10, 95%CI 1.35-3.25; P = .01), electrophysiology dedicated laboratory (OR 2.45, 95%CI 1.48-4.05; P < .01) and use of contact force enabled catheter (OR 22.60, 95%CI 6.82-74.88; P < .01).</p><p><strong>Conclusion: </strong>This real-life study of fluoroscopy use during AF ablation provides new data about current practices across European countries. Technological advances and quality of the fluoroscopic environment were the main factors associated with lower radiation dose during AF ablation.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1853-1860"},"PeriodicalIF":1.8,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39449609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of the cardio-ankle vascular index for recurrence of atrial fibrillation after catheter ablation.","authors":"Masaya Shinohara,&nbsp;Tadashi Fujino,&nbsp;Ryo Wada,&nbsp;Kensuke Yano,&nbsp;Katsuya Akitsu,&nbsp;Hideki Koike,&nbsp;Toshio Kinoshita,&nbsp;Takanori Ikeda","doi":"10.1111/pace.14373","DOIUrl":"https://doi.org/10.1111/pace.14373","url":null,"abstract":"<p><strong>Background: </strong>The predictive value of the cardio-ankle vascular index (CAVI) for estimating the efficacy outcome of catheter ablation (CA) in atrial fibrillation (AF) patients is unclear. We aimed to examine the predictive performance of the CAVI for recurrences of atrial arrhythmias after CA.</p><p><strong>Methods: </strong>We enrolled a total of 193 patients with AF (paroxysmal 126 and non-paroxysmal 67) who underwent initial CA procedures at our institute, and CAVI measurements were conducted between January 2016 and March 2017. We evaluated recurrences of atrial arrhythmias after the first CA procedure as a clinical outcome. The CAVI value was assessed and the enrolled patients were divided according to the optimal CAVI value cut-off point (9.5) in the atrial arrhythmia recurrence group.</p><p><strong>Results: </strong>During a mean follow-up of 31.3 (17.5-43.0) months, 74 (32.5%; PaAF 41 and 49.3%; non-PaAF 33) patients had recurrences of atrial arrhythmias. The recurrence ratio of atrial arrhythmias was significantly higher in patients with a high CAVI (≥9.5) than those with a low CAVI (<9.5) (log rank test; p = 0.018). A univariate analysis showed the association between higher CAVI values and recurrences of atrial arrhythmias (p = 0.072). Multivariate analyses using a Cox proportional hazard model after adjusting for other clinical factors revealed that the CAVI value was determined to be a significant predictive factor of a recurrence of atrial arrhythmias after CA (Hazard ratio: 1.44, 95% confidence interval: 1.17-1.78, p < 0.01).</p><p><strong>Conclusions: </strong>The CAVI was significantly associated with a recurrence of atrial arrhythmias after CA in AF patients.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1861-1873"},"PeriodicalIF":1.8,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39507159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right ventricular dilatation and systolic dysfunction and relationship to QRS duration in patients with left bundle branch block and cardiomyopathy.","authors":"Seung-Jung Park,&nbsp;Deborah H Kwon,&nbsp;John W Rickard,&nbsp;Niraj Varma","doi":"10.1111/pace.14357","DOIUrl":"https://doi.org/10.1111/pace.14357","url":null,"abstract":"<p><strong>Background: </strong>Marked QRS widening in patients with left bundle branch block (LBBB) may reduce efficacy of cardiac resynchronization therapy (CRT). We hypothesized that extreme QRS prolongation may accompany right ventricular (RV) dilatation/systolic dysfunction (RVD/RVsD) as well as left ventricular dilatation/systolic dysfunction (LVD/LVsD).</p><p><strong>Methods: </strong>We assessed rates of both ventricular dilatation and systolic dysfunction according to widening of QRS duration (QRSd) in 100 consecutive cardiomyopathy patients with true LBBB (QRSd ≥ 130 ms in female or ≥140 ms in male, QS or rS in leads V1/V2, and mid-QRS notching/slurring in ≥2 contiguous leads of I, aVL, and V1/V2/V5/V6). Ventricular dimensions and function were measured by cardiac magnetic resonance imaging.</p><p><strong>Results: </strong>There was a trend toward an increase in the prevalence of LVD (13%, 20%, and 90%), LVsD (67%, 77%, and 90%), RVD (23%, 27%, and 50%), RVsD (27%, 27%, and 40%), RVD plus RVsD (13%, 17%, and 40%), or RVD/RVsD (37%, 37%, and 50%) according to the degree of QRS prolongation (<150 ms, n = 30; 150-180 ms, n = 60; and ≥180 ms, n = 10). Similarly, patients in the highest quartile of QRSd (QRSd ≥ 168 ms, n = 26) showed greater rates of RVD (23% vs. 44%, p = .069), RVsD (22% vs. 48%, p = .032), RVD plus RVsD (10% vs. 30%, p = .040), or RVD/RVsD (33% vs. 57%, p = .050) compared to those in the remaining quartiles (n = 74). QRSd ≥ 180 ms was identified as an independent predictor for the presence of RVD plus RVsD.</p><p><strong>Conclusion: </strong>The rates of RVD and/or RVsD increased with QRS widening, particularly when QRSd exceeded 180 ms. This may diminish anticipated CRT response rates in cardiomyopathy patients with LBBB.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1890-1896"},"PeriodicalIF":1.8,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/pace.14357","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39398910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New-onset atrial fibrillation in the medical intensive care unit: Catch me if you can.","authors":"Maria E Vadakken,&nbsp;Emilie P Belley-Cote,&nbsp;William F McIntyre","doi":"10.1111/pace.14370","DOIUrl":"https://doi.org/10.1111/pace.14370","url":null,"abstract":"Atrial fibrillation (AF) is often first detected in an acute setting. Prior studies have reported a wide range of estimates of the incidence of new-onset AF during acute medical illness in an intensive care unit (ICU) setting, ranging from 3% to 44%.1 New-onset AF in critically ill patients has been associatedwithworse outcomes includingmortality; however, optimal management strategies remain unclear. We read with interest the retrospective observational cohort study by Brunetti et al., involving 2234 patients with a medical ICU stay.2 They identified new-onset AF in 10.8% of patients (95%CI 9.5%– 12.2%) using ICD-10 codes that were validatedmanually through ECG and chart review. As compared to patients without AF, patients with new-onset AF had greater odds of in-hospital mortality (21.2% vs. 10.3%, odds ratio [OR] = 1.9, 95%CI 1.3–2.7). Among patients with new-onset AF who survived the index hospitalization, 18.9% (95%CI 13.6%–25.3%) had a recurrence of AF in the first year following discharge. The authors ascertained AF recurrence by manually reviewing records for 12-lead and ambulatory ECGs. We recently estimated the incidence of new-onset AF lasting at least 30 s in critically ill patients at 18.9% (95%CI 14.2%−24.3%).3 This estimate is higher than that of Brunetti’s group; differences are likely explained by different study designs. We applied a 14-day continuous ECG patch at ICU admission. In the ICU, all patients also underwent standard continuous ECG monitoring. Interestingly, the clinical team recognized only 70%of episodes detected by the patch; clinicianswere more likely to recognize longer episodes of AF. Although we do not know theminimum duration of AF that confers an increased risk, using continuous monitoring and collecting the episode duration is the most rigorous way to evaluate these episodes. The long-term management of patients with new-onset AF during an acute illness is unclear. The AF Occurring Transiently with Stress (AFOTS) follow-up study is systematically examining the long-term outcomes of patients with new-onset AF during hospitalization for intercurrent noncardiac illness or surgery.4 Participants with new-onset AF are matched to control participants for age, sex, and nature of illness. Study participants are in sinus rhythm at discharge and wear a 14-day Holter 1 and 6months after discharge. Whilewe await the results of this study, we urge readers to consider the influence of continuous ECG monitoring on the incidence of newonset AF in hospitalized patients and to re-assess the long-term need for oral anticoagulation in these patients after hospital discharge.","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1952"},"PeriodicalIF":1.8,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39468640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A strategy of idarucizumab for pericardial tamponade during perioperative period of atrial fibrillation ablation.","authors":"Xin Zhao,&nbsp;Li-Zhu Chen,&nbsp;Xin Su,&nbsp;De-Yong Long,&nbsp;Cai-Hua Sang,&nbsp;Rong-Hui Yu,&nbsp;Ri-Bo Tang,&nbsp;Rong Bai,&nbsp;Nian Liu,&nbsp;Chen-Xi Jiang,&nbsp;Song-Nan Li,&nbsp;Xue-Yuan Guo,&nbsp;Wei Wang,&nbsp;Xin Du,&nbsp;Jian-Zeng Dong,&nbsp;Chang-Sheng Ma","doi":"10.1111/pace.14344","DOIUrl":"https://doi.org/10.1111/pace.14344","url":null,"abstract":"<p><strong>Objective: </strong>To investigate theoptimal idarucizumab (dabigatran antagonist) usage strategy for patients with acute pericardial tamponade receiving uninterrupted dabigatran during catheter ablation for atrial fibrillation (AF).</p><p><strong>Methods: </strong>Ten patients presenting acute pericardial tamponade while receiving uninterrupted dabigatran during catheter ablation for AF in Beijing Anzhen Hospital from January 2019 to July 2020 were enrolled and retrospectively analyzed. A \"wait and see\" strategy of idarucizumab was carried out for all patients; in brief, idarucizumab was applied following pericardiocentesis, comprehensive evaluation of bleeding and hemostasis.</p><p><strong>Results: </strong>There were five males, five paroxysmal AF, and the average age of the patients was 64.0 ± 9.8 years. Among the 10 patients, four were treated with dabigatran 110 mg, six were treated with dabigatran 150 mg, and one was simultaneously given clopidogrel. The average time from pericardial tamponade to the last dose of dabigatran was 8.2 ± 3.4 h. All patients underwent pericardiocentesis successfully, and the average drainage volume was 322.5 ml (220.0 ± 935.0 ml). For reversal anticoagulation, six patients received protamine, and five patients received idarucizumab. Of the five patients who were treated with idarucizumab, four presented exact hemostasis, except for one patient who underwent continuous drainage and finally received surgery repair. The average time to restart anticoagulation was 1.1 ± 0.3 days after the procedure, and no rebleeding, embolism or deaths were observed.</p><p><strong>Conclusion: </strong>The \"wait and see\" strategy of idarucizumab for acute pericardial tamponade during the perioperative period of catheter ablation for AF may be safe and feasible.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1824-1831"},"PeriodicalIF":1.8,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/pace.14344","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39352554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A left ventricular assist device interfering with leadless pacemaker implantation.","authors":"Jeffrey Smietana,&nbsp;Andrea Schell,&nbsp;Naga Venkata K Pothineni,&nbsp;Katie Walsh,&nbsp;David Lin","doi":"10.1111/pace.14332","DOIUrl":"https://doi.org/10.1111/pace.14332","url":null,"abstract":"<p><p>Left ventricular assist devices (LVAD) produce electromagnetic interference (EMI) which can have implications when patients require cardiac implantable electronic devices. Leadless pacemakers have been successfully implanted in patients with Heartmate 2 and Heartmate 3 LVADs without evidence of EMI or device-to-device interaction. Here we report a case of a Heartmate 3 LVAD and Micra VR transcatheter pacing system interaction requiring device repositioning.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1949-1951"},"PeriodicalIF":1.8,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/pace.14332","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39275558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-arrhythmic and anti-heart failure effects of low-level electrical stimulation on aortic root ventricular ganglionated plexi.","authors":"Hong-Tao Wang,&nbsp;Hong-Ke Sun,&nbsp;Ai-Ping Jin,&nbsp;Wei Jiang,&nbsp;Yan Zhang,&nbsp;Fei-Fei Su,&nbsp;Qiang-Sun Zheng","doi":"10.1111/pace.14261","DOIUrl":"https://doi.org/10.1111/pace.14261","url":null,"abstract":"<p><strong>Background: </strong>It remains uncertain whether low-level electrical stimulation (LL-ES) of the ventricular ganglionated plexi (GP) improves heart function. This study investigated the anti-arrhythmic and anti-heart failure effects of LL-ES of the aortic root ventricular GP (ARVGP).</p><p><strong>Methods: </strong>Thirty dogs were divided randomly into control, drug, and LL-ES groups after performing rapid right ventricular pacing to establish a heart failure (HF) model. The inducing rate of arrhythmia; levels of bioactive factors influencing HF, including angiotensin II type I receptor (AT-1R), transforming growth factor-beta (TGF-β), matrix metalloproteinase (MMP), and phosphorylated extracellular signal-regulated kinase (p-ERK1/2); left ventricular stroke volume (LVSV), and left ventricular ejection fraction (LVEF)were measured after treatment with placebo, drugs, and LL-ES.</p><p><strong>Results: </strong>The inducing rate of atrial arrhythmia decreased from 60% in the control group to 50% in the drug group and 10% in the LL-ES group (p = .033 vs. drug group) after 1 week of treatment. The ventricular effective refractory period was prolonged from 139 ± 8 ms in the drug group to 166 ± 13 ms in the LL-ES group (p = .001). Compared to the drug group, the expressions of AT-1R, TGF-β, and MMP proteins were down-regulated in the LL-ES group, whereas that of p-ERK1/2 was significantly increased (all p = .001). Moreover, in the LL-ES group, LVSV increased markedly from 13.16 ± 0.22 to 16.86 ± 0.27 mL, relative to that in the drug group (p = .001), and LVEF increased significantly from 38.48% ± 0.53% to 48.94% ± 0.57% during the same time frame (p = .001).</p><p><strong>Conclusion: </strong>Short-term LL-ES of ARVGP had both anti-arrhythmic and anti-inflammatory effects and contributed to the treatment of tachycardia-induced HF and its associated arrhythmia.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1817-1823"},"PeriodicalIF":1.8,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/pace.14261","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38980054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of CIEDs with automatic \"wireless\" remote monitoring on efficiency.","authors":"Brynn E Dechert,&nbsp;David J Bradley,&nbsp;Gerald A Serwer,&nbsp;Martin J LaPage","doi":"10.1111/pace.14333","DOIUrl":"https://doi.org/10.1111/pace.14333","url":null,"abstract":"<p><strong>Background: </strong>A benefit of automatically transmitting or \"wireless\" CIEDs (W-CIED) is the prompt detection of device malfunction and arrhythmias. We hypothesized that the use of W-CIEDs would improve the efficiency of remote monitoring by decreasing unnecessary CIED remote transmissions because of the automatic detection of abnormalities.</p><p><strong>Objective: </strong>To compare the frequency of patient-initiated transmissions in patients with W-CIEDs versus non-wireless CIEDs (NW-CIED) at a single pediatric and congenital heart center.</p><p><strong>Methods: </strong>Retrospective cohort study of patients with W-CIEDs followed over a 2-year period compared to a similar cohort of patients with NW-CIED. All CIED remote transmissions during were reviewed for indication and outcome.</p><p><strong>Results: </strong>The W-CIED cohort had 87 patients; mean age 20 ± 13 years; NW-CIED cohort had 220 patients; mean age 22 ± (13) years. The mean number of symptomatic patient-initiated transmissions per patient was 0.93 ± 2.65 in the W-CIED cohort versus 0.39 ± 0.64 in the NW-CIED cohort (p ≤ .001). The mean number of asymptomatic patient-initiated transmission sent per patient in the W-CIED cohort was 1.86 ± 2.59 versus 0.81 ± 1.41 in the NW-CIED cohort (p ≤ .0001). Type of device, age, and presence of congenital heart disease were not significantly associated with the incidence of patient-initiated remote monitoring transmissions.</p><p><strong>Conclusions: </strong>The frequency of patient-initiated transmission was higher in the W-CIED cohort, contradictory to the study hypothesis. This may reflect a lack of patient understanding of the benefit or functionality of W-CIEDs and may be mitigated by education to both providers and patients.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1671-1674"},"PeriodicalIF":1.8,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/pace.14333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39286845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of safety and feasibility of leadless pacemaker implantation following the removal of an infected pacemaker.","authors":"Jianghua Zhang,&nbsp;Long He,&nbsp;Qiang Xing,&nbsp;Xianhui Zhou,&nbsp;Yaodong Li,&nbsp;Ling Zhang,&nbsp;Yanmei Lu,&nbsp;Zukela Tuerhong,&nbsp;Xu Yang,&nbsp;Baopeng Tang","doi":"10.1111/pace.14346","DOIUrl":"https://doi.org/10.1111/pace.14346","url":null,"abstract":"<p><strong>Background: </strong>Leadless pacemakers provide safe and effective pacing options for patients with device-related infections. This study was aimed at observing and evaluating the safety and feasibility of extracting an infected pacemaker device followed by the implantation of a leadless pacemaker in the same location for patients without systemic infection.</p><p><strong>Methods: </strong>Between December 2019 and September 2020, following a well-planned re-implantation strategy, pacemaker electrodes were removed from patients with device infection and leadless pacemakers were immediately implanted at our center. The patients were then followed up for up to 10 months to assess the safety and practicality of the procedure.</p><p><strong>Results: </strong>Pacemaker electrode removal and immediate leadless pacemaker implantation were successfully achieved in eight patients with pocket infection. After a minimum follow-up period of 1 month and a maximum follow-up of 10 months, the pacing parameters for the patients remained stable and there was no infection at the original capsular bag or in the leadless pacemaker.</p><p><strong>Conclusion: </strong>Direct implantation of a leadless pacemaker is safe and feasible for patients with local infection of the pacing system after removal of the electrode as an alternative to a bridge period with a temporary pacemaker. This strategy may be a better option for pacing-dependent patients.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1711-1716"},"PeriodicalIF":1.8,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/pace.14346","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39365953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}